RobertMGrossbergMD
Infectious Disease • Bronx, NYHIV/AIDS Medicine, Mycobacterial Disease
Professor, Medicine, Infectious Diseases, Albert Einstein College of Medicine
Dr. Grossberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
MMC Dept of Medicine
111 East 210TH Street
Bronx, NY 10467Phone+1 718-920-5224Fax+1 718-405-0610
Summary
- Dr. Robert Grossberg is an infectious disease specialist based in Bronx, NY, with subspecialties in HIV/AIDS Medicine and Mycobacterial Disease. He completed his fellowship and residency in Infectious Disease and Internal Medicine, respectively, at the University of Pennsylvania Health System, following his graduation from The Warren Alpert Medical School of Brown University in 1996. Currently a professor at Albert Einstein College of Medicine, Dr. Grossberg has contributed to prominent research publications, notably in the fields of COVID-19 and HIV, with studies published in Clinical Infectious Diseases and The Lancet. His research work extends to clinical trials focusing on treatments for multi-drug resistant HIV and the role of financial incentives in substance use treatment.
Education & Training
University of Pennsylvania Health SystemFellowship, Infectious Disease, 1999 - 2001- University of Pennsylvania Health SystemResidency, Internal Medicine, 1996 - 1999
The Warren Alpert Medical School of Brown UniversityClass of 1996
Certifications & Licensure
NY State Medical License 2004 - 2025
PA State Medical License 1997 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Project FIRST - Financial Incentives to Reduce Substance Use and Improve Treatment Start of enrollment: 2012 Jun 01
- Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Start of enrollment: 2015 Aug 01
- Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1 Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- 4 citationsA Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVI...Catharine I Paules, Jing Wang, Kay M Tomashek, Tyler Bonnett, Kanal Singh
Annals of Internal Medicine. 2024-03-01 - 2 citationsEvaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case.Ana M Ortega-Villa, Noreen A Hynes, Corri B Levine, Katherine Yang, Zanthia Wiley
Open Forum Infectious Diseases. 2023-06-01 - 8 citationsAnorectal Testing for Mpox Virus Infection in Men Who Have Sex With Men With and Without Proctitis.Eric A Meyerowitz, Inessa Gendlina, Vimi J Desai, Robert Grossberg, Singh R Nair
Clinical Infectious Diseases. 2023-03-04
Press Mentions
Paxlovid Use for COVID-19 May Be Feasible in Advanced CKDJuly 15th, 2022- Meningitis Vaccine May Guard Against GonorrheaApril 13th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
